Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter, Multi-Cohort Phase II Clinical Study (STELLAR01)

NCT07530094 is registered in ClinicalTrials.gov with Ning Jiang, M.D./Ph.D. as lead sponsor.

NCT NCT07530094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07530094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter, Multi-Cohort Phase II Clinical Study (STELLAR01)
Lead sponsor
Ning Jiang, M.D./Ph.D.
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2025
Completion date
December 1, 2027
Enrollment
98 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced unresectable esophageal squamous cell carcinoma